NCT02954874 2026-04-13
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT03503799 2026-04-13
RESCUE
North Eastern German Society of Gynaecological Oncology
Active not recruiting
NCT05812807 2026-04-07
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05601440 2026-03-27
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07447440 2026-03-11
RESOLBE
Clinica Universidad de Navarra, Universidad de Navarra
Recruiting
NCT02492607 2026-01-26
LORD
The Netherlands Cancer Institute
Phase NA Active not recruiting
NCT06718010 2026-01-21
The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
Fudan University
Recruiting